Novavax (NASDAQ: NVAX) reported Q1 EPS of ($1.05), $0.13 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $93.85 million versus the consensus estimate of $141.16 million.

GUIDANCE:

Novavax sees FY2024 revenue of $800 million to $1 billion, versus the consensus of $845.5 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.